Treatment of levodopa-induced motor complications

被引:88
作者
Stocchi, Fabrizio [1 ]
Tauliati, Michele [2 ]
Olanow, C. Warren [2 ]
机构
[1] IRCCS San Raffaele, I-00163 Rome, Italy
[2] Mt Sinai Sch Med, New York, NY USA
关键词
advanced Parkinson's disease; dyskinesias; motor fluctuations; levodopa; dopamine agonists;
D O I
10.1002/mds.22052
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Chronic levodopa treatment for Parkinson's disease patients is frequently associated with the development of motor complications such as end-of-dose wearing-off and dyskinesias. fit this review. we provide in overview of the strategies available for dealing with these problems. Medical management includes manipulation of levodopa closing to establish the optimum treatment schedule. improving levodopa absorption, catechol-O-methyl transferase-inhibition (COMT), Monoamine oxidase-B (NIAO-B) inhibition, dopaminergic agonists, amantadine, and continuous dopaminergic infusions Surgical procedures and particularly deep brain stimulation are also reviewed. It should be noted that none of these treatments has been shown to provide anti-parkinsonian efficacy that is greater than what can be achieved with levodopa. W highlight the importance of initiating therapy with it treatment strategy that reduces the risk that a Parkinson's disease patient will develop motor complications in the first place. Key Words: Advanced PD. dykinesias, motor fluctuations. levodopa, dopamine agonists, COMT inhibitors, MAO-B inhibitors. (c) 2008 Movement Disorder Society.
引用
收藏
页码:S599 / S612
页数:14
相关论文
共 155 条
[11]   Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease [J].
Baron, MS ;
Dalton, WB .
MOVEMENT DISORDERS, 2003, 18 (10) :1208-1209
[12]   Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study [J].
Baron, MS ;
Vitek, JL ;
Bakay, RAE ;
Green, J ;
Kaneoke, Y ;
Hashimoto, T ;
Turner, RS ;
Woodard, JL ;
Cole, SA ;
McDonald, WM ;
Delong, MR .
ANNALS OF NEUROLOGY, 1996, 40 (03) :355-366
[13]   INFLUENCE OF MEAL INGESTION TIME ON PHARMACOKINETICS OF ORALLY-ADMINISTERED LEVODOPA IN PARKINSONIAN-PATIENTS [J].
BARUZZI, A ;
CONTIN, M ;
RIVA, R ;
PROCACCIANTI, G ;
ALBANI, F ;
TONELLO, C ;
ZONI, E ;
MARTINELLI, P .
CLINICAL NEUROPHARMACOLOGY, 1987, 10 (06) :527-537
[14]   Pallidal stimulation for Parkinson's disease - Two targets? [J].
Bejjani, B ;
Damier, P ;
Arnulf, I ;
Bonnet, AM ;
Vidailhet, M ;
Dormont, D ;
Pidoux, B ;
Cornu, P ;
Marsault, C ;
Agid, Y .
NEUROLOGY, 1997, 49 (06) :1564-1569
[15]   Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders [J].
Benabid, AL ;
Pollak, P ;
Gao, DM ;
Hoffmann, D ;
Limousin, P ;
Gay, E ;
Payen, I ;
Benazzouz, A .
JOURNAL OF NEUROSURGERY, 1996, 84 (02) :203-214
[16]  
BENABID AL, 1987, APPL NEUROPHYSIOL, V50, P344
[17]   Levedracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque [J].
Bezard, E ;
Hill, MP ;
Crossman, AR ;
Brotchie, JM ;
Michel, A ;
Grimée, R ;
Klitgaard, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 485 (1-3) :159-164
[18]   A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease [J].
Bibbiani, F ;
Oh, JD ;
Petzer, JP ;
Castagnoli, N ;
Chen, JF ;
Schwarzschild, MA ;
Chase, TN .
EXPERIMENTAL NEUROLOGY, 2003, 184 (01) :285-294
[19]   Neuroleptic malignant-like syndrome and acute hepatitis during tolcapone and clozapine medication [J].
Blum, MW ;
Siegel, AM ;
Meier, R ;
Hess, K .
EUROPEAN NEUROLOGY, 2001, 46 (03) :158-160
[20]   WEARING-OFF FLUCTUATIONS IN PARKINSONS-DISEASE - CONTRIBUTION OF POSTSYNAPTIC MECHANISMS [J].
BRAVI, D ;
MOURADIAN, MM ;
ROBERTS, JW ;
DAVIS, TL ;
SOHN, YH ;
CHASE, TN .
ANNALS OF NEUROLOGY, 1994, 36 (01) :27-31